No Data
No Data
4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC Capital
4D Molecular Therapeutics Price Target Maintained With a $40.00/Share by RBC
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
RBC Capital analyst Lisa Walter maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 25
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BMO Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
BMO Capital analyst Kostas Biliouris maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Domino's Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results.The company reported second-quarter FY24 sales growth of 7.1% year-